Evidence brief · Supplement
Piracetam for Cognition (healthy young)
Evidence grade D — Weak
- Overall grade
- Grade D
- Last revised
- 1
- graded outcome
- 0
- references listed
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
1 at grade D — 1 graded row
What is known
Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.
- Cognition (healthy young)Evidence grade D
Weak
Triviallow
What is uncertain
Read off the same rows as above. Nothing here is added that the entry does not itself record.
- Thin evidence: Cognition (healthy young) (grade D).
The evidence in words
The verdict
For cognition (healthy young), Piracetam earns evidence grade D (trivial effect, low consistency) — the evidence does not support the claim. Weak
How it might work
It modulates neuronal membrane fluidity and cholinergic/glutamatergic signaling and improves microcirculation; the mechanism is still not fully pinned down.
How to use it
Safety & cautions
Generally well tolerated; headaches (often eased by adding choline) are common.
Bottom line
Real evidence in cognitive decline, weak in healthy users, and legally grey. Not a proven study aid for the average person.
Goes with
- PiracetamRead the full Piracetam monographEvidence grade C
Related reading
Entries that share this one's tags or conditions.
- Oxiracetam for CognitionEvidence grade D — SparseEvidence grade D
- Noopept for CognitionEvidence grade D — Limited Western dataEvidence grade D
- OxiracetamA stimulating racetam with sparse, dated human evidence.Evidence grade D
- Piracetam for Cognition (impairment/elderly)Evidence grade C — Better than in healthyEvidence grade C
Sources
This entry lists no references of its own — it is assembled from the entries it links to, whose sources are on their pages.
Last revised . A grade is this entry's reading of the evidence, not medical advice.